Physician profile
Lawrence A Young
NPI 1568444388
$4,463.62
in general payments reported to CMS, 2019-2025
44 companies · $870 in 2025
The $870 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $906 · 2022: $805 · 2023: $844 · 2024: $1,039 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $626.07 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $473.09 | 2021-2025 | Breztri, Airsupra, Lokelma |
| Teva Pharmaceuticals USA, INC. | $353.15 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $275.12 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $191.43 | 2022-2025 | |
| Amgen INC. | $153.00 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $148.64 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.79 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $128.50 | 2021-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.41 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $103.81 | 2021-2025 | Rexulti |
| Biogen, INC. | $67.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $65.63 | 2022 | |
| Supernus Pharmaceuticals, INC. | $63.52 | 2024-2025 | Qelbree |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.